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 The prevalence of obesity has markedly increased over 
the last few decades not only in wealthy industrialized 
countries, but also in poor underdeveloped nations ( 1 ). 
Obesity and overweight have adverse health effects and af-
fect the risk and prognosis of many serious medical condi-
tions, such as type 2 diabetes, coronary heart disease, high 
blood pressure, and some forms of cancer. Obesity causes 
excess fat accumulation not only in various tissues, particu-
larly adipose tissues, but also in other insulin-responsive 
organs such as the skeletal muscle and liver, predisposing 
one to the development of insulin resistance ( 2–5 ). How-
ever, the molecular mechanisms underlying insulin resis-
tance and obesity have not been fully clarifi ed, and 
effective therapeutic approaches are currently of general 
interest. 
 Peroxisome proliferator-activated receptors (PPAR) - a , 
- g , and - d are FA-activated nuclear transcription factors 
that control mRNA expression of numerous genes in-
volved in energy metabolism ( 6–8 ). In particular, PPAR a 
is expressed mostly in tissues with high rates of FA oxida-
tion and peroxisomal metabolism ( 9 ), such as the liver, 
brown fat, and heart ( 10–12 ). In these tissues, PPAR a reg-
ulates mRNA expression of genes involved in FA oxida-
tion, and synthetic PPAR a agonists, such as fi brates, 
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 MATERIALS AND METHODS 
 Animal experiments 
 All the mice were maintained in a temperature-controlled 
(23°C) facility with a constant 12 h light/dark cycle and free ac-
cess to water. For the analysis of organ PPAR a expression levels, 
8-week-old male C57BL/6 mice (CLEA Japan, Tokyo, Japan) 
were fed a standard diet (CRF-1, Charles River Japan, Tokyo, Ja-
pan). Non-fasted, fasted (24 h), and fasted (24 h)/refed (24 h) 
C57BL/6 mice were used before euthanization. After euthaniza-
tion, their tissues were harvested for RNA isolation. The har-
vested tissues were immediately frozen in liquid nitrogen and 
stored at  2 80°C until use. We used male C57BL/6 mice fed ei-
ther the standard diet or 60% HFD (D12492 Research Diet, MO) 
for 12 months for the diet-induced obese model mice. Male ob/
ob mice and lean control mice (age 12 weeks from Charles River 
Japan) received a standard diet for genetically obese mice. 
 To investigate the effect of the PPAR a agonist on adipose tis-
sue metabolism, we used KK mice or WT and PPAR a  2 / 2  mice 
with a Sv/129 genetic background. Five-week-old male KK (CLEA 
Japan) mice were maintained for fi ve to eight weeks either on 
HFD or on HFD containing 0.2% bezafi brate. The energy intake 
of all mice was adjusted by pair-feeding. Five to eight weeks after 
feeding, the mice were subjected to analyses of their oxygen con-
sumption, locomotor activity, oral glucose tolerance test (OGTT), 
insulin tolerance test (ITT), mRNA expression, FA oxidation in 
isolated adipocytes, and histological features. Eight-week-old WT 
and PPAR a  2 / 2  mice were fed HFD or HFD containing 0.2% 
bezafi brate for six weeks. The same amount of food was given to 
all mice. Ten h after fasting, tissues were harvested for RNA anal-
ysis. The animal care procedures and methods were approved by 
the Animal Care Committee of Kyoto University. 
 To analyze the oxygen consumption of mice, male KK mice 
fed HFD or HFD containing 0.2% bezafi brate for fi ve weeks were 
used. The oxygen consumption rate (OCR) of mice under the 
fed condition was measured using an indirect calorimetric system 
(Oxymax, Columbus Instruments, OH) every 9 min for 20 h. The 
measurements started at 9:00 PM and ended at 6:00 PM (both 
the dark and light phases were 10 h). 
 Male KK mice were maintained for fi ve weeks either on HFD 
or HFD containing 0.2% bezafi brate. For OGTT, d-glucose (2 g/
kg body weight) was administered through a gastric feeding tube 
after overnight fasting. For ITT, human insulin (Eli Lilly Japan, 
Kobe, Japan) was injected intraperitoneally (0.6 units/kg body 
weight) into nonfasted animals. Blood samples were collected 
from the tail vein before and 30, 60, 90, and 120 min after injec-
tion. Plasma glucose level was determined by the glucose C -test 
Wako (Wako Pure Chemicals, Osaka, Japan) in accordance with 
the manufacturer’s protocols. 
 Epididymal WAT was removed from each animal, fi xed in 10% 
formaldehyde/PBS, and maintained at 4°C until use. The fi xed 
samples were embedded in paraffi n. They were cut into 12 µm 
sections using a microtome and mounted on silanized slides. Adi-
pocyte size distribution was determined using National Institutes 
of Health (NIH) Image J software. 
 Cell culture and retrovirus-mediated PPAR  expression 
 To prepare stromal-vascular (SV) cells and adipocytes from 
WAT, epididymal WAT from male mice was removed under ster-
ile conditions and washed in KRH buffer (20 mM HEPES, 140 
mM NaCl, 5 mM KCl, 2.5 mM MgSO 4 , 1 mM CaCl 2 ; pH 7.4). 
Minced tissue was transferred to a sterile polypropylene tube con-
taining collagenase (1 mg/ml, type II, Sigma) and 1% FA-free 
BSA (BSA). After incubation at 37°C for 45 min with shaking, the 
digested tissue was fi ltered through a sterile 250  m m nylon mesh. 
decrease circulating lipid levels and are commonly used to 
treat hyperlipidemia and other dyslipidemic states ( 9, 
13 ). PPAR a -defi cient (PPAR a  2 / 2  ) mice exhibit higher 
levels of serum triglyceride (TG) ( 14 ). Moreover, these 
mice show extensive hepatic lipid accumulation and in-
creased gonadal adipose storage and plasma FFA levels 
( 15 ). In addition, the presence of severe hypoketonemia, 
hypoglycemia, and hypothermia in PPAR a  2 / 2  mice 
clearly supports a function of PPAR a in metabolic 
regulation. 
 Previous studies showed that adipose tissue dysfunction 
plays an important role in the development of obesity and 
obesity-associated diseases ( 16, 17 ). Adipose tissue also 
participates in the regulation of energy homeostasis as an 
important endocrine organ that secretes many biologi-
cally active molecules called adipocytokines ( 16–19 ). The 
secretion pattern of adipocytokines is closely related to 
adipocyte condition ( 18 ). Small adipocytes secrete insulin-
sensitizing hormones such as adiponectin, although hy-
pertrophied adipocytes exhibit low expression levels of 
these factors but increased expression levels of hormones 
related to insulin resistance, such as such as tumor necrosis 
factor- a (TNF a ), monocyte chemoattractant protein-1 
(MCP-1), and interleukin-6 (IL-6), resulting in insulin 
resistance observed in obesity ( 19 ). Indeed, thiazolidine-
diones (TZD), insulin sensitizers, promote differentiation 
of preadipocytes by PPAR g activation to increase the num-
ber of small adipocytes and to decrease the number of hy-
pertrophied adipocytes by promoting apoptosis ( 20 ). 
 Besides their hypolipidemic effects, PPAR a activators at-
tenuate adiposity in animal models of obesity and type-2 
diabetes mellitus ( 21, 22 ). Recently, several studies have 
shown that PPAR a is expressed in the adipose tissue of 
humans and rodents, indicating that adipose tissue might 
also be a target organ of PPAR a activators ( 22–25 ). Hiuge 
et al. demonstrated that fi brates directly and transcription-
ally increase adiponectin expression level via adipose 
PPAR a ( 23 ). Furthermore, it was suggested that PPAR a 
ligands directly stimulate lipolysis in wild-type (WT) adipo-
cytes, but this effect is not observed in PPAR a -defi cient 
adipocytes ( 25 ). These previous fi ndings indicate that 
PPAR a functions in adipocytes. However, the role of 
PPAR a in adipose tissue is not fully understood. 
 In this study, we investigated whether PPAR a activation 
affects the energy metabolism in white adipose tissue 
(WAT). Treatment with bezafi brate, a PPAR a agonist, 
markedly attenuated adiposity in WT mice but not in 
PPAR a  2 / 2  mice fed a high-fat diet (HFD). Both genetic 
and HFD-induced obesity decreased PPAR a mRNA ex-
pression level, and fasting increased the expression level 
in WAT. PPAR a activation promoted both adipocyte dif-
ferentiation and FA oxidation in 3T3-L1 adipocytes. These 
effects were also observed in vivo, which resulted in the 
enhancement of whole-body oxygen consumption and 
suppression of adipocyte hypertrophy. These fi ndings in-
dicate that the pharmacological activation of PPAR a af-
fects energy metabolism in adipocytes and that the PPAR a 
activation in WAT may contribute to the clinical effects of 
fi brate drugs. 
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volume. Tubes containing cells and buffer were inverted several 
times to obtain a homogenous mixture, and equal aliquots of 
each sample were distributed into 50 ml polystyrene tubes. [ 14 C]
palmitic acid was added at a fi nal concentration of 1  m Ci/ml. The 
tubes with a piece of fi lter paper soaked in benzethonium hy-
droxide were then sealed and incubated at 37°C for 2 h. The 
tubes were gently shaken every 30 min during the incubation. 
After 2 h, 12 M HCl was added to the cells to release [ 14 C]CO 2 , 
and each tube was resealed and incubated at 37°C overnight. The 
amount of [ 14 C]CO 2 released was measured by scintillation 
counting of the fi lter paper. Radioactivity was normalized to ge-
nomic DNA content in each packed cell. Packed cells were incu-
bated overnight with proteinase K (150  m g/ml). Genomic DNA 
was purifi ed using phenol/chloroform, and its content was quan-
tifi ed by measuring the absorbance at 260 nm. 
 Measurement of OCR in 3T3-L1 cells 
 Cellular OCR was measured using a Seahorse Bioscience XF24 
analyzer ( 30 ) in 24-well plates at 37°C, with correction for posi-
tional temperature variations adjusted from 4 empty wells evenly 
distributed within the plate. L1-Mock or L1-PPAR a cells were 
induced to differentiate and were maintained for 10 days with 
or without the PPAR a agonist GW7647. Immediately before the 
measurement, cells were washed, and 675  m l of nonbuffered 
(sodium-carbonate-free) pH 7.4 DMEM medium supplemented 
with 0.2 mM palmitic acid, 0.2 mM l-carnitine, and 2% FA-free 
BSA was added to each well. After a 15 min equilibration period, 
four successive 1.5 min measurements were performed at 7 min 
intervals with intermeasurement mixing to homogenize the oxy-
gen concentration in the medium. Rotenone (fi nal concentra-
tion of 100 nM) was injected to each well using the internal 
injectors of the cartridge, and four successive 1.5 min measure-
ments were performed at 7 min intervals with intermeasurement 
mixing. 
 Measurements of TG content and GPDH activity 
 To determine intracellular TG amount, 3T3-L1 cells grown in 
12-well plates were washed with PBS, and lipids were extracted by 
hexane-isopropyl alcohol (3:2, v/v) for 1 h at room temperature. 
Aliquots were transferred and evaporated under a decreased 
pressure. Samples were resuspended in 10% TritonX-100 in iso-
propyl alcohol, and TG content was measured enzymatically 
using triglyceride G test Wako (Wako Pure Chemicals). For Oil Red 
O staining, 3T3-L1 cells 10 days after the induction of differentia-
tion were fi xed with 10% formaldehyde/PBS and stained with 
Oil Red O solution [0.5% Oil Red O-isopropyl alcohol/H 2 O (3:2, 
v/v)]. 
 Cells were washed twice with PBS and collected with a cell 
scraper into 25 mM Tris-HCl (pH 7.4) containing 1 mM EDTA. 
The harvested cells were sonicated for 5 s at 40 watts with a mi-
croson ULTRASONIC CELL DISRUPTOR (Misonix, Inc., NY). 
After centrifugation at 12,800  g for 5 min at 4°C, the superna-
tants were assayed for glycerol-3-phosphate dehydrogenase 
(GPDH) activity as described elsewhere ( 31 ). 
 RNA analysis 
 Total RNA was prepared from mouse tissues or cultured 3T3-
L1 and human multipotent adipose tissue-derived stem adipo-
cytes using Qiazol lysis reagent (QIAGEN, CA) or Sepasol(R)-RNA 
I Super (Nacalai Tesuque) in accordance with the manufac-
turer’s protocol. Total RNA was reverse-transcribed using 
M-MLV reverse transcriptase (Promega, WI) in accordance with the 
manufacturer’s instructions using a thermal cycler (Takara PCR 
Thermal Cycler SP, Takara, Shiga, Japan). To visualize and com-
pare the expression levels of PPAR a and 36B4, semiquantitative 
The digested tissue was centrifuged at 200  g for 2 min, and mature 
adipocytes and SV cells were collected. Both cell types were 
washed twice by centrifugation using KRH buffer containing 1% 
FA-free BSA. After washing, cells were subjected to each assay. 
 3T3-L1 murine preadipocytes (from American Type Culture 
Collection, Manassas, VA) were cultured as previously described 
( 26 ). Human multipotent adipose tissue-derived stem cells were 
cultured as previously reported ( 27 ). Cells 14 days after the in-
duction of differentiation were used as mature adipocytes. 
 A PCR fragment coding mouse PPAR a obtained by RT-PCR 
using total liver RNA from C57BL/6 mice was inserted into the 
site between BamHI and NotI of pMX-puro (a kind gift from Dr. 
T. Kitamura, University of Tokyo, Tokyo, Japan) (pMX-PPAR a ). 
The PCR primers used were as follows: the 5 ′ -primer, TTTG-
GATCCATGGTGGACACAGAGAGCCCCATC; and the 3 ′ -primer, 
TTTGCGGCCGCTCAGTACATGTCTCTGTAGATCTCTTGC. 
Plat-E cells (kindly provided by Dr. Naohito Aoki, Mie University, 
Tsu, Japan) were cultured in a growth medium at 37°C in 5% 
CO 2 . The pMX-PPAR a was transfected into Plat-E packaging cells 
using Lipofectamine2000 (Invitrogen, CA) in accordance with 
the manufacturer’s instructions. Viral supernatants were har-
vested 48 h after transfection. Viral supernatants were applied to 
3T3-L1 cells in the growth medium supplemented with 5  m g/ml 
polybrene. To eliminate uninfected cells, the medium was re-
placed with a growth medium containing 2.5  m g/ml puromycin. 
 Insulin-stimulated 2-deoxy-d-glucose uptake assay 
 The level of uptake of 2-deoxy-d-[1,2- 3 H]glucose (2-DG) was 
measured as previously described ( 26 ). Briefl y, 10 days after dif-
ferentiation induction, 3T3-L1 cells were deprived of serum by 
incubation for 5 h in 12-well plates containing DMEM. The cells 
were then incubated with 100 nM insulin for 20 min in 450 µl of 
KRH buffer containing 1% FA-free BSA. Glucose uptake was initi-
ated by adding 50 µl KRH buffer containing 1 mM 2-deoxy-d-
[1,2- 3 H]glucose (1 µCi) (American Radiolabeled Chemicals, 
MO) to each well, and after 10 min, uptake was terminated by 
washing the cells three times with ice-cold PBS buffer. The cells 
were solubilized with 0.1N NaOH, and incorporated radioactivity 
was measured by liquid scintillation counting. The radioactivity 
was normalized to protein content determined by the method of 
Bradford (Bio-Rad Laboratories, CA). 
 FA oxidation assay 
 Ten days after differentiation induction, 3T3-L1 cells overex-
pressing PPAR a (L1-PPAR a ) or control cells (L1-Mock) were in-
cubated in DMEM containing 0.2 mM palmitic acid, 2.5% FA-free 
BSA, 200  m M l-carnitine, and [ 14 C]palmitic acid (1  m Ci/ml) 
(American Radiolabeled Chemicals) for 16 h. FA oxidation prod-
ucts were assessed as previously described ( 28 ) with modifi cation. 
Briefl y, the labeling medium was collected and centrifuged, and 
the supernatant was transferred to a 50-ml polypropylene tube. 
An uncapped Eppendorf tube containing a piece of fi lter paper 
soaked in benzethonium hydroxide was placed inside a 50 ml 
tube. After the tube was sealed, 200  m l of 70% perchloric acid was 
added to the medium sample to release [ 14 C]CO 2 . The tube was 
then shaken at 37°C for 1 h. The saturated fi lter paper contain-
ing trapped [ 14 C]CO 2 was assessed for radioactivity in a liquid 
scintillation counter. The acidifi ed medium was centrifuged 
twice to remove particulate matter, and 200  m l of supernatant was 
assessed for the amount of [ 14 C]labeled acid-soluble FA metabo-
lites (ASM). 
 FA oxidation with isolated adipocytes was analyzed as previ-
ously described ( 29 ). In brief, isolated adipocytes were prepared 
from epididymal WAT and washed in KRH with 1% BSA. A fresh 
buffer was added to the cells at a volume twice the packed cell 
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were represented as a ratio relative to that of the control in each 
experiment. 
 Immunoblotting 
 Total cellular proteins were solubilized in lysis buffer (50 mM 
Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 
0.1% SDS; pH 7.4) and a protease inhibitor cocktail). The pro-
tein concentration of samples was determined using a protein 
assay kit (Bio-Rad Laboratories). Protein samples (30  m g) were 
subjected to SDS-PAGE on a 10% gel. Separated proteins were 
transferred electrophoretically to PVDF membranes (Millipore, 
MA), which were blocked with 5% nonfat dried milk in pho sphate-
buffered saline. The membranes were incubated with antibodies 
to PPAR a (Perseus Proteomics, Tokyo, Japan) and  b -actin (Cell 
Signaling Technology, MA), and then with peroxidase-conjugated 
anti-mouse and anti-rabbit IgG antibodies (Santa Cruz, CA), 
respectively. Proteins were detected using an ECL Western blot-
ting detection system (GE Healthcare, NJ). 
 Chromatin immunoprecipitation (ChIP) assay 
 3T3-L1 cells 14 days after differentiation induction were fi xed 
with 1% formaldehyde in PBS for 10 min. The cells were then 
rinsed twice with ice-cold PBS containing 2% bovine serum and 
0.05% NaN 3 , centrifuged for 5 min at 3,000 rpm, and resus-
pended in lysis buffer [1% SDS, 10 mM EDTA, 50 mM Tris-HCl 
(pH 8.0), and a protease inhibitor cocktail]. Following incuba-
tion for 20 min on ice, samples were sonicated on ice. The lysates 
were centrifuged at 15,000 rpm for 10 min, and the collected su-
pernatant was diluted in buffer [1.1% Triton X-100, 0.11% so-
 Fig.  1. Effects of PPAR a activator on adiposity and insulin resistance. A, B: White adipose tissue (WAT) weight from male mildly obese 
KK mice (A) and wild-type (WT) or PPAR a -defi cient (PPAR a  2 / 2  ) mice (B) fed high-fat diet control (Cont) or high-fat diet containing 0.2% 
bezafi brate (Beza) for four and six weeks. In each experiment, the mice were housed under pair-fed conditions. C, D: Plasma glucose levels 
during oral glucose tolerance test (GTT) (C) and insulin tolerance test (ITT) (D). Both GTT and ITT were performed on KK mice fed 
high-fat diet (Cont) or high-fat diet containing 0.2% bezafi brate (Beza) for fi ve weeks under pair-fed condition. Plasma glucose level was 
measured by enzymatic colorimetric assay. Data are means ± SEM of 4-6 animals per group. * P < 0.05, ** P < 0.01, compared with control 
diet group. 
PCR was performed. PCR amplifi cation was performed with de-
naturation at 94°C for 20 s, annealing at 60°C for 40 s, and poly-
merization at 72°C for 20 s. PCR was performed for 35 cycles. 
PCR products were electrophoresed on 2% agarose gels and 
stained with ethidium bromide. To quantify mRNA expression, 
real-time RT-PCR was performed with a LightCycler System 
(Roche Diagnostics, Mannheim, Germany) using SYBR Green 
fl uorescence signals as described previously ( 31–34 ). The oligo-
nucleotide primers of mouse and human 36B4 and PPAR a , 
mouse adipogenic marker genes, and PPAR a target genes were 
designed using a PCR primer selection program in the website of 
the Virtual Genomic Center from the GenBank database. All oli-
gonucleotide primer sets used to measure the expression levels 
of 36B4, adipocyte fatty-acid-binding protein (aP2), PPAR g , and 
adiponectin were previously described ( 31–34 ). The primers 
used for measurements of the mRNA expression levels of other 
genes (upstream and downstream, respectively) were TCAGGG-
TACCACTACGGAGT and CTTGGCATTCTTCCAAAGCG for 
mouse PPAR a mRNA; ACTCCACCTGCAGAGCAACCA and 
TAGATCTCCTGCAGTAGCGGG for human PPAR a mRNA; 
GCACCATTGCCATTCGATACA and CCACTGCTGTGAGAAT-
AGCCGT for acyl-CoA oxidase (ACO) mRNA; CTGTTAGGCCT-
CAACACCGAAC and CTGTCATGGCTAGGCTGTACAT for 
carnitine-palmitoyl transferase-1b (CPT1b) mRNA; and TAC-
CCAACCTTGGCTAGACCTC and GCAACTTCTCCTTGATGA-
TGTCGTA for uncoupling protein 3 (UCP3) mRNA. To compare 
mRNA expression level among the samples, the copy numbers of 
all transcripts were divided by that of mouse 36B4 showing a con-
stant expression level in adipocytes. All mRNA expression levels 
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 PPAR  expression level increased during adipocyte 
differentiation in 3T3-L1 cells and changed depending on 
energy condition in WAT 
 We next examined the expression of PPAR a in cultured 
adipocytes and WAT. As previously reported ( 22, 23 ), PPAR a 
mRNA was highly expressed in the liver, brown adipose tis-
sue, and kidney (supplementary Fig. IA, B). The PPAR a 
mRNA expression level in WAT was higher than that in the 
skeletal muscle, although that in WAT was lower than that in 
tissues with high mRNA expression level of PPAR a (supple-
mentary Fig. IA, B). In WAT, PPAR a mRNA was expressed at 
a higher level in the adipocyte fraction than in the SV cell 
fraction (supplementary Fig. IC). In cultured 3T3-L1 cells, 
the mRNA expression level of PPAR a increased in parallel 
with the progression of adipocyte differentiation and in a 
pattern similar to that of adiponectin mRNA expression 
( Fig. 2A ).  In human multipotent adipose tissue-derived stem 
cells characterized by an extensive proliferative potential 
and the ability to undergo multilineage differentiation, in-
cluding adipogenic differentiation ( 27 ), adipogenic induc-
dium deoxycholate, 167 mM NaCl, 50 mM Tris-HCl; (pH 8.0) 
and a protease inhibitor cocktail)]. Samples were precleared 
with 5 µg of sheared salmon sperm DNA and 50  m l of protein 
A/G-Sepharose beads (Santa Cruz) for 2 h. Immunoprecipita-
tion with the antibody to PPAR a or normal mouse IgG (Santa 
Cruz) was performed overnight. Samples were then incubated 
with 20 µl of protein A/G-Sepharose beads for 3 h followed by 10 
min sequential washes in RIPA I (0.1% SDS, 1% Triton X-100, 
0.1% sodium deoxycholate, 2 mM EDTA, 50 mM Tris-HCl, and 
150 mM NaCl; pH 8.0), RIPA II (0.1% SDS, 1% Triton X-100, 
0.1% sodium deoxycholate, 2 mM EDTA, 50 mM Tris-HCl, 500 
mM NaCl; pH 8.0), buffer III (0.25M LiCl, 0.5% Nonidet P-40, 
0.5% sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl; 
pH8.0), and Tris-EDTA buffer. Precipitates were then extracted 
by incubating with elution buffer (0.5% SDS, 5 mM EDTA, 300 
mM NaCl, 10 mM Tris-HCl; pH8.0) at 65°C overnight. After the 
RNase A and proteinase K treatment, DNA fragments were puri-
fi ed with phenol/chloroform. Purifi ed samples were used as tem-
plates for PCR performed for 35 cycles. Oligonucleotide primers 
composed of the following sequences (upstream and down-
stream) were used for PCR: aP2, GAATTCCAGCAGGAATCAGG 
and GCCAAAGAGACAGAGGGCG (300 bp); CPT1b, CCTGT-
GCTGGTCCCCAACTCACAGC and CTCCTGGTGACCTTTTC-
CCTACAT T (279 bp). 
 Statistical analysis 
 The data were expressed as means ± S.E.M. Statistical sig-
nifi cance was evaluated using unpaired Student’s  t -test for the 
two groups. The results were considered signifi cant at  P < 
0.05. 
 RESULTS 
 Administration of PPAR  agonist attenuated adiposity 
and improved insulin resistance in mice fed HFD 
 To study the effect of PPAR a activation on energy me-
tabolism in WAT, we treated mice fed HFD with bezafi -
brate, a PPAR a agonist. Since PPAR a agonists have been 
shown to reduce food intake in rodents ( 35 ), all mice were 
housed in pair-fed conditions in each experiment. Admin-
istration of bezafi brate (0.2%) in mildly obese diabetic KK 
mice fed HFD for four weeks signifi cantly decreased adi-
posity (50, 49, and 54% decrease in epididymal, perirenal, 
and mesenteric WAT, respectively) ( Fig. 1A and supple-
mentary Table I).  Because bezafi brate has been reported 
to activate other PPAR subtypes ( 36 ), we used PPAR a  2 / 2  
and WT (control) mice, and a similar experiment was per-
formed. For a six-week treatment, bezafi brate signifi cantly 
reduced adiposity in WT mice similarly to KK mice ( Fig. 
1B and supplementary Table II). However, this effect was 
not observed in PPAR a  2 / 2  mice. Although the WAT 
weight was slightly higher in PPAR a  2 / 2  mice than in WT 
mice, the difference was not statistically signifi cant. These 
results indicate that pharmacological PPAR a activation re-
duces adiposity independently of its anorexic effect. Next, 
to examine the effect of a PPAR a agonist on insulin sensi-
tivity, we carried out a GTT and ITT. Plasma glucose levels 
in both tests in the bezafi brate-treated mice were signifi -
cantly lower than those in the pair-fed control mice ( Fig. 
1C, D ), indicating that a PPAR a agonist ameliorates HFD-
induced insulin resistance in KK mice. 
 Fig.  2. mRNA expression levels of PPAR a in cultured cells and 
WAT. A, B: mRNA expression levels of murine PPAR a and adi-
ponectin or human PPAR a during adipocyte differentiation. 3T3-
L1 cells and human multipotent adipose tissue-derived stem cells 
were harvested at the indicated times after differentiation induc-
tion. Semiquantitative PCR conditions are described in “Materials 
and Methods.” C, D: mRNA expression levels of PPAR a in WAT in 
obese model mice and lean control mice. PPAR a mRNA expres-
sion levels in C57BL/6 mice fed high-fat diet (HFD) or normal diet 
(control) for 12 months (C) and in ob/ob mice or lean control 
mice (D) were quantifi ed by a real-time PCR as described in “Mate-
rials and Methods.” E: The mRNA expression levels of PPAR a in 
WAT in C57BL/6 under fed (control), fasted (24 h), and fasted/
refed (24 h after refeeding) conditions were quantifi ed by real-
time PCR. Data are means ± SEM of 4-6 animals per group. * P < 
0.05, ** P < 0.01. 
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 Fig.  3. PPAR a activation increased mRNA expression levels of marker factors for adipocyte differentiation but not TG content. A: PPAR a 
expressions in WAT and cultured cells. PPAR a mRNA levels in several WATs [subcutaneous (Sub), mesenteric (Mes), perirenal (Rea), and 
epididymal (Epi) WAT from C57BL/6 mice], stromal-vascular (SV) cells from epididymal WAT in C57BL/6 mice, and cultured cells [3T3-
L1 cells overexpressing PPAR a (L1-PPAR a ), mock control (L1-Mock), RAW264.7 macrophages, and LPS-stimulated RAW264.7 mac-
rophages] were visualized by semiquantitative PCR (left). PPAR a protein levels in L1-Mock and L1-PPAR a were visualized by Western 
blotting (right). B-F: L1-Mock and L1-PPAR a cells were induced to differentiate and cultured with or without GW7647 (30 or 100 nM) for 
6-10 days. B-E: The mRNA expression levels of adipogenic marker genes ( aP2 and  PPAR g ) (on day 10) (B), glycerol-3-phosphate dehydro-
genase (GPDH) activity (on day 6) (C), the capacity of insulin-stimulated 2-DG transport (on day 10) (D), and intracellular triglyceride 
(TG) amounts (E) in L1-Mock and L1-PPAR a were determined as described in “Materials and Methods.” F: Microscopy views of representa-
tive L1-Mock and L1-PPAR a cells treated with or without 100 nM GW7647, fi xed with formalin, and stained with Oil Red O. The original 
magnifi cation is 100×. Data are means ± SEM; n = 4-6. * P < 0.05, ** P < 0.01 compared with DMSO-treated L1-Mock cells.  # P < 0.05,  ## P < 
0.01 compared with L1-Mock cells treated with the same compounds. G, H: 3T3-L1 cells were induced to differentiate and cultured with or 
without GW7647 (300 nM) and GW6471 (100 nM) for 10 days. The mRNA expression levels of  aP2 and  PPAR g (G) and microscopy views 
of representative cells stained with Oil Red O (H). The original magnifi cation is 100×. Data are means ± SEM; n = 4. * P < 0.05, ** P < 0.01. 
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 PPAR  activation entirely correlated with increases in 
adipogenic gene expression level, GPDH activity, and 
insulin-stimulated glucose uptake level but not with lipid 
accumulation level in 3T3-L1 cells 
 To investigate the direct effect of PPAR a activation 
on adipocyte metabolism, we examined PPAR a -agonist-
treated 3T3-L1 adipocytes. Because the PPAR a mRNA ex-
pression level was much lower in 3T3-L1 cells before 
differentiation induction than in murine SV cells included 
with preadipocytes ( Fig. 3A ),  we established 3T3-L1 cells 
overexpressing PPAR a mRNA (L1-PPAR a ) and mock con-
trol cells (L1-Mock). The mRNA and protein expression 
levels of PPAR a in L1-PPAR a cells were slightly higher 
than those in SV cells ( Fig. 3A ). First, we examined the 
effects of PPAR a activation on adipocyte differentiation. 
GW7647, highly a specifi c PPAR a activator, was added at 
the time of differentiation induction and kept in the me-
 Fig.  4. Effects of PPAR a activation on FA oxidation in cultured adipocytes. A-D: 3T3-L1 cells overexpress-
ing PPAR a (L1-PPAR a ) and mock control (L1-Mock) cells were induced to differentiate and cultured with 
or without GW7647 (30 or 100 nM) for 10 days. The mRNA expression levels of genes involved in FA oxida-
tion ( ACO ,  CPT1b , and  UCP3 ) (A), oxidation of [ 14 C]palmitic acid to CO 2 (B), and acid-soluble FA metabo-
lites (ASM) (C) for 16 h, and oxygen consumption rate (OCR) (D) in L1-Mock and L1-PPAR a was determined 
as described in “Materials and Methods.” Data are means ± SEM; n = 3-6. * P < 0.05, ** P < 0.01 compared with 
DMSO-treated L1-Mock.  # P < 0.05,  ## P < 0.01 compared with L1-Mock treated with the same compounds. E: 
3T3-L1 cells were induced to differentiate and cultured with or without GW7647 (300 nM) and GW6471 
(100 nM) for 10 days. The mRNA expression levels of  ACO and  CPT1b was measured by real-time PCR. Data 
are means ± SEM; n = 4. ** P < 0.01. 
tion also induced PPAR a mRNA expression ( Fig. 2B ). 
Because diet-induced obesity and fasting affects the hepatic 
expression of PPAR a ( 37, 38 ), we assessed whether PPAR a 
mRNA expression level in WAT changes depending on en-
ergy condition. The PPAR a mRNA expression in WAT was 
signifi cantly decreased in both HFD-induced obese mice (12 
months) ( Fig. 2C ) and the genetically obese mouse model 
(ob/ob) ( Fig. 2D ) compared with the lean control mice. In 
the HFD-fed and ob/ob mice, the PPAR a mRNA expression 
level in WAT decreased by 54 and 40%, respectively. Con-
versely, 24 h fasting increased PPAR a mRNA expression 
level by 1.5-fold ( Fig. 2E ). The extent of increase was dimin-
ished by refeeding after 24 h ( Fig. 2E ). These fi ndings indi-
cate that PPAR a mRNA expression in WAT is changed 
depending on the energy condition, suggesting that PPAR a 
physiologically and pharmacologically plays an important 
role in the control of energy balance. 
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 Fig.  5. Effects of PPAR a activator on adipocyte differentiation and FA oxidation in WAT. KK mice (A, B, E-G) and wild-type (WT) or 
PPAR a -defi cient (PPAR a  2 / 2  ) mice (C, D) fed HFD (Cont) or HFD containing 0.2% bezafi brate (Beza) were housed under the pair-fed 
condition for 4-6 weeks. A-D: The mRNA expression levels of adipogenic marker genes ( aP2 ,  PPAR g , and  adiponectin ) (A, C) and genes 
involved in FA oxidation ( ACO ,  CPT1b , and  UCP3 ) (B, D) in WAT were determined by real-time PCR. E-G: Oxidation of [ 14 C]palmitic acid 
to CO 2 in isolated adipocytes (E), microscopy views of representative histological sections of epididymal WAT (F), and adipocyte size distri-
bution in epididymal WAT (G) from mice fed each experimental diet for 6 weeks were examined. Data are means ± SEM; n = 3-8. * P < 0.05, 
** P < 0.01 compared with mice fed control diet. 
dium throughout the differentiation period. As shown in 
 Fig. 3B , the addition of GW7647 induced the mRNA ex-
pression of adipogenic marker genes, such as those encod-
ing aP2 and PPAR g . Furthermore, the GW7647 treatment 
increased both lipogenic enzyme GPDH activity (on day 6) 
and insulin-stimulated 2-DG uptake capacity (on day 10) 
( Fig. 3C, D ). The effects of GW7647 depended on GW7647 
concentration and exogenous PPAR a expression. These 
results indicate that PPAR a activation promotes adipocyte 
differentiation. However, surprisingly, the TG content 
was markedly lower in L1-PPAR a than in L1-Mock in the 
presence of 100 nM GW7647 ( Fig. 3E, F ), although the 
lipogenic GPDH activity and insulin-stimulated 2-DG up-
take capacity were higher in L1-PPAR a than in L1-Mock, 
as shown above. Even in unmanipulated 3T3-L1 cells, 
GW7647 induced aP2, PPAR g , and adiponectin expres-
sion and lipid accumulation during adipocyte differentia-
tion ( Fig. 3G, H ). In contrast, the addition of the PPAR a 
antagonist GW6471 inhibited them ( Fig. 3G, H ). Thus, in 
3T3-L1 cells, PPAR a activation may be associated with adi-
pocyte differentiation physiologically. 
 PPAR  activation enhanced fatty acid oxidation and 
OCR in 3T3-L1 cells 
 To clarify the inhibitory effect of PPAR a activation on 
lipid accumulation, we examined GW7647-induced FA 
oxidation in L1-PPAR a . Transient GW7647 treatment did 
not affect the amount of glycerol release or FFA release 
under our experimental conditions (data not shown). 
Furthermore, the mRNA expression levels of lipases 
(hormone-sensitive lipase and adipose triglyceride lipase) 
related to lipolysis in adipocytes were not changed by the 
GW7647 treatment (data not shown). On the other hand, 
chronic GW7647 treatment during adipocyte differentia-
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tion induced the mRNA expression of genes involved in 
FA oxidation, such as those encoding ACO, CPT1b, and 
UCP3 ( Fig. 4A ).  The induction was observed to be more 
marked in L1-PPAR a than in L1-Mock. When cells were 
incubated with [ 14 C]palmitic acid for 16 h, the GW7647 
treatment enhanced the oxidation of [ 14 C]palmitic acid to 
CO 2 and acid-soluble FA metabolites ( Fig. 4B, C ). More-
over, OCR determined by extracellular fl ux analysis ( 30 ) 
was increased by the GW7647 treatment ( Fig. 4D ). Rote-
none, an inhibitor of mitochondrial electron transport, 
almost completely diminished the increase in OCR. These 
fi ndings indicate that PPAR a activation in adipocytes en-
hances FA oxidation and increases OCR via the induction 
of PPAR target genes related to FA oxidation, suggesting 
that the effects of PPAR a activation contribute to the dis-
crepancy between adipogenic activity and lipid accumu-
lation levels induced by PPAR a activation. Even in 
unmanipulated 3T3-L1 cells, GW7647 induced ACO and 
CPT1b expression ( Fig. 4E ). In contrast, the addition of a 
PPAR a antagonist GW6471 inhibited it ( Fig. 4E ). There-
fore, PPAR a activation might play some physiological roles 
in fatty acid oxidation in 3T3-L1 cells. 
 PPAR  activation induced both adipogenic and 
FA-oxidation-related genes in WAT and enhanced FA 
oxidation in isolated adipocytes and the entire body 
 Next, we examined whether the effects of PPAR a activa-
tion observed in cultured adipocytes were observed in vivo. 
Treatment of KK mice fed HFD with bezafi brate for four 
weeks signifi cantly increased the expression levels of both 
adipogenic marker genes ( aP2 ,  PPAR g , and  adiponectin ) 
and genes involved in FA oxidation ( ACO ,  CPT1b , and 
 UCP3 ) ( Fig. 5A , B ).  Similar mRNA inductions by bezafi brate 
administration for six weeks were observed in WT mice but 
not in PPAR a  2 / 2  mice ( Fig. 5C, D ), suggesting that PPAR a 
plays an essential role in the induction of genes involved in 
both adipogenesis and FA oxidation in WAT by the bezafi -
brate treatment. Using an indirect calorimetric system, we 
found that OCR was higher in the bezafi brate-treated mice 
than in the control KK mice (supplementary Fig. IIA), de-
spite nearly the same locomotor activity (data not shown). 
Because these mice were fed HFD, the respiratory exchange 
ratio (RER) was always low during this measurement; how-
ever, the RER of the bezafi brate-treated mice was slightly 
but signifi cantly lower in the light phase (supplementary 
Fig. IIB). Moreover, the capacity for the oxidation of [ 14 C]
palmitic acid to CO 2 was higher in the isolated adipocytes of 
the bezafi brate-treated mice ( Fig. 5E ). The size of adipo-
cytes was smaller in epididymal WAT from the bezafi brate-
treated mice ( Fig. 5F, G ). These fi ndings were similar to 
those in cultured cells and indicate that PPAR a activation 
induced adipogenesis and FA oxidation in WAT, resulting 
in suppression of adipocyte hypertrophy. 
 PPAR  seemed to be recruited to the promoter region of 
genes involved in both adipogenesis and FA oxidation in 
3T3-L1 cells 
 Finally, to confi rm whether PPAR a was recruited to the 
promoter region, which contained an identifi ed PPAR-
response element (PPRE), of genes related to adipogenesis 
and FA oxidation in 3T3-L1 cells, we performed ChIP as-
say. We focused on  aP2 as an adipogenic gene and  CPT1b 
as an FA oxidation gene. As shown in  Fig. 6 ,  in the pres-
ence of GW7647, ChIP assay revealed that PPAR a recruit-
ment to the promoter regions of both  aP2 and  CPT1b was 
enhanced in 3T3-L1 cells 14 days after differentiation in-
duction. These regions have been shown to contain PPRE 
( 39, 40 ); it was suggested that PPAR a activation by ligand 
binding enhanced the direct binding of PPAR a to PPRE. 
 DISCUSSION 
 Several recent studies have demonstrated that PPAR a is 
expressed in WAT of humans and rodents ( 22–24 ). WAT 
plays a key role in regulating whole-body energy metabo-
lism. In this study, we attempted to clarify the functions of 
PPAR a in WAT. We found that the mRNA expression level 
of PPAR a in WAT was decreased by diet-induced and ge-
netic obesity and, conversely, was increased by fasting. 
These fi ndings suggest that the PPAR a activity in WAT 
plays a physiological role in energy metabolism. PPAR a  2 / 2  
mice exhibited increased adiposity and adipocyte hyper-
trophy ( 41 ). Moreover, these phenotypes seemed to be 
independent of the hepatic PPAR a action ( 41 ). The fi nd-
ings in PPAR a  2 / 2  mice were in contrast to those in 3T3-L1 
cells treated with a PPAR a agonist in this study. 
 A number of reports have shown that PPAR a is particu-
larly important during fasting ( 11, 15, 38, 42 ). Fasted 
PPAR a  2 / 2  mice suffer from various metabolic defects, in-
cluding hypoketonemia, hypothermia, and hypoglycemia. 
During the fasting period, lipolysis in WAT releases glyc-
erol and FA into the blood. It has been reported that 
PPAR a activators stimulate lipolysis in WAT ( 25 ). There-
fore, it is suggested that the increase in PPAR a mRNA ex-
pression level in WAT during fasting is important for 
adaptation to fasting. 
 Moreover, several studies have shown that the number 
of mitochondrial DNA copies and the expression levels of 
mitochondrial genes are decreased in WAT of obese ani-
mal models and humans ( 29, 43, 44 ). In the diabetic state, 
the mitochondrial  b -oxidation of FA is attenuated. In ad-
dition, mitochondria show abnormal morphologies ( 44 ). 
In this study, the increase in OCR ( Fig. 4D ) was almost di-
 Fig.  6.  ChIP assays of aP2 and CPT1b promoter in 3T3-L1 adipo-
cytes treated with or without GW7647. ChIP assays were performed 
as described in “Materials and Methods.” Soluble chromatin from 
3T3-L1 cells, whose differentiation was induced and maintained 
for 14 days with or without of 30 nM GW7647, was immunoprecipi-
tated with control mouse IgG (lanes 2 and 4) or antibodies against 
PPAR a (lanes 3 and 5). Immunoprecipitates were analyzed by PCR 
using specifi c primers for the mouse aP2 or CPT1b promoter re-
gion containing potential PPRE. PCR was performed with total 
chromatin input (lane 1). 
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adipocyte differentiation, and its synthesized agonists, thi-
azolidinediones, potently facilitate adipocyte differentia-
tion to improve insulin resistance ( 18–20 ). In this study, 
the treatment with a PPAR a agonist induced the mRNA 
expression of adipogenic genes, such as  aP2 and  PPAR g , at 
higher levels in PPAR a -expressing 3T3-L1 cells (L1-
PPAR a ) than in control 3T3-L1 cells (L1-Mock). In addi-
tion, the induction of these genes was observed only in WT 
mice but not in PPAR a  2 / 2  mice. These observations sug-
gest that PPAR a activation can promote adipocyte differ-
entiation. The effect of PPAR a on adipocyte differentiation 
was confi rmed by ChIP assay, showing that PPAR a was re-
cruited to PPRE in each promoter region of adipogenic 
genes directly regulated by PPAR g in WAT. A previous 
study has also shown that PPAR a activation induces the 
mRNA expression of glycerol kinase ( 58 ), which catalyzes 
the direct conversion of glycerol to glycerol-3-phosphate 
in human adipocytes. Glycerol-3-phosphate is an impor-
tant material for FA esterifi cation to form TG in adipo-
cytes. Thus, it is suggested that a PPAR a -specifi c adipogenic 
pathway exists, although the effect of PPAR a seems to be 
partially shared with that of PPAR g . 
 We provided experimental evidence that PPAR a activa-
tion in adipocytes leads to the promotion of both adipo-
cyte differentiation and the FA oxidation pathway. These 
effects of PPAR a activation are caused by the direct bind-
ing of PPAR a to PPRE located in the promoter regions of 
genes involved in adipocyte differentiation and FA oxida-
tion. We also demonstrated that PPAR a expression level 
in WAT is changed by several nutrient conditions, such as 
obesity and fasting. Because adipocytes are closely related 
to whole-body carbohydrate and lipid metabolism, PPAR a 
activity in WAT may play an important role in regulating 
whole-body energy metabolism. Furthermore, PPAR a in 
WAT may contribute to the improvement of obesity-
induced metabolic disorders, such as insulin resistance, in 
combination with fi brate drugs.  
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